Does Skyrizi List Upper Respiratory Infections as a Side Effect?
Yes, upper respiratory infections occur in patients taking Skyrizi (risankizumab-rzaa), an IL-23 inhibitor for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Clinical trials reported them in 14-29% of Skyrizi users versus 13-24% on placebo, with rates varying by condition and dose.[1][2]
How Common Are They in Trials?
- Plaque psoriasis: 14% (Skyrizi) vs. 13% (placebo).
- Psoriatic arthritis: 22% vs. 20%.
- Crohn's disease: 29% vs. 24%.
Most cases were mild to moderate and did not lead to discontinuation.[1][2]
Why Does Skyrizi Increase Infection Risk?
Skyrizi suppresses IL-23, part of the immune system that fights infections, including respiratory ones. This raises susceptibility to upper respiratory infections like colds, sinusitis, or bronchitis, especially in the first year of treatment.[1][3]
What Do Real-World Patients Report?
Post-marketing data and patient forums note upper respiratory infections as frequent, often within weeks of starting. Some describe recurring sinus issues or colds lasting longer than usual.[4]
When Should You Worry About Infections?
Seek medical help if infections include fever over 100.4°F, persistent cough, shortness of breath, or worsening symptoms—signs of serious issues like pneumonia. Skyrizi carries a boxed warning for infections.[1][2]
How Does This Compare to Other Biologics?
Skyrizi's rate is similar to Stelara (13-25%) but lower than TNF inhibitors like Humira (up to 40%). Head-to-head data is limited.[3][5]
[1]: Skyrizi Prescribing Information (FDA)
[2]: Skyrizi Clinical Trial Data (AbbVie)
[3]: Drugs.com - Skyrizi Side Effects
[4]: FDA Adverse Event Reporting System (FAERS) Summary
[5]: GoodRx - Biologic Infection Risks